Literature DB >> 24699210

The social value of mortality risk reduction: VSL versus the social welfare function approach.

Matthew D Adler1, James K Hammitt2, Nicolas Treich3.   

Abstract

We examine how different welfarist frameworks evaluate the social value of mortality risk reduction. These frameworks include classical, distributively unweighted cost-benefit analysis--i.e., the "value per statistical life" (VSL) approach-and various social welfare functions (SWFs). The SWFs are either utilitarian or prioritarian, applied to policy choice under risk in either an "ex post" or "ex ante" manner. We examine the conditions on individual utility and on the SWF under which these frameworks display sensitivity to wealth and to baseline risk. Moreover, we discuss whether these frameworks satisfy related properties that have received some attention in the literature, namely equal value of risk reduction, preference for risk equity, and catastrophe aversion. We show that the particular manner in which VSL ranks risk-reduction measures is not necessarily shared by other welfarist frameworks.
Copyright © 2014 Elsevier B.V. All rights reserved.

Keywords:  Cost–benefit analysis; Equity; Risk policy; Social welfare functions; Value of statistical life

Mesh:

Year:  2014        PMID: 24699210     DOI: 10.1016/j.jhealeco.2014.02.001

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  3 in total

1.  Underprotection of Unpredictable Statistical Lives Compared to Predictable Ones.

Authors:  Marc Lipsitch; Nicholas G Evans; Owen Cotton-Barratt
Journal:  Risk Anal       Date:  2016-07-09       Impact factor: 4.000

2.  Willingness to pay for morbidity and mortality risk reductions during an epidemic. Theory and preliminary evidence from COVID-19.

Authors:  Luciana Echazu; Diego C Nocetti
Journal:  Geneva Risk Insur Rev       Date:  2020-08-13

3.  Welfare economics of managing an epidemic: an exposition.

Authors:  Yasushi Iwamoto
Journal:  Jpn Econ Rev (Oxf)       Date:  2021-10-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.